Skip to main content

Dyskinesia: What to Do about Moving Too Much

January 21, 2016

In this webinar we discuss dyskinesia, involuntary movements that arise with levodopa use as Parkinson's progresses. Our panelists discuss the current management of dyskinesia and new therapies in development.

Webinar Details


Thursday, January 21, 2016


1 hr


12:00 pm ET

  • Continuing Medical Education Information

    MJFF offers Continuing Medical Education (CME) credit for practicing health care professionals for each Third Thursday Webinar. Click the link in the Resource List after viewing the webinar to take the post-test survey and receive your CME credit.

    Date of Original Release: January 21, 2016
    Date CME Credit No Longer Available: January 21, 2018

    Learning Objectives

    At the conclusion of this course, participants should be able to:

    • Define the clinical features of levodopa-induced dyskinesia.
    • Explain the potential pathogenetic mechanisms of levodopa-induced dyskinesia.
    • Discuss approaches for management of levodopa-induced dyskinesia.
    • Summarize ongoing research into anti-dyskinetic therapies.
    Target Audience

    This educational activity is designed for primary care physicians, family practice physicians, general medicine physicians, geriatricians, general neurologists, movement disorder specialists and any other health care practitioners who manage patients with Parkinson's disease.


    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Oakstone Publishing, LLC and The Michael J. Fox Foundation for Parkinson's Research. The Oakstone Publishing, LLC is accredited by the ACCME to provide continuing medical education for physicians.

    Oakstone Publishing, LLC designates this enduring material for 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


    Oakstone Publishing, LLC has assessed conflict of interest with its faculty, authors, editors and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest were resolved for fair balance and scientific objectivity of studies utilized in this activity. Oakstone Publishing, LLC's planners, content reviewers, and editorial staff disclose no relevant commercial interests.


    Christopher Bishop, PhD
    Professor of Psychology
    Binghamton University
    No disclosures

    Joseph Jankovic, MD
    Professor of Neurology
    Distinguished Chair in Movement Disorders
    Director, Parkinson's Disease Center and Movement Disorders Clinic
    Baylor College of Medicine
    Research Grants: Adamas Pharmaceuticals, Inc; Allergan, Inc; Civitas/Acorda Therapeutics; Ipsen Limited; Kyowa Haako Kirin Pharma, Inc; Lundbeck Inc; Medtronic; Merz Pharmaceuticals; Omeros Corporation; Pfizer; Prothena Biosciences Inc; Psyadon Pharmaceuticals, Inc; St. Jude Medical; Teva Pharmaceutical Industries Ltd.
    Advisory Role: Adamas Pharmaceuticals, Inc; Allergan, Inc; Teva Pharmaceutical Industries Ltd

    Dave Iverson
    No disclosures

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.